380 completed, 95 recruiting, 58 unknown, 47 active not recruiting. 678 Phase 3, 127 Phase 2.
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight Zenagamtide, Placebo ( matched to Zenagamtide) - Obesity, Overweight | Phase 3 | Not yet recruiting | Novo Nordisk A/S | 400 | 2027-01-07 | 2026-08-24 |
| A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease Enicepatide, Placebo - Overweight, Obesity | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 8200 | 2027-01-06 | 2026-11-05 |
| A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes AZD6234, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | AstraZeneca | 330 | 2027-01-04 | 2026-11-06 |
| Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Tirzepatide, Placebo - Obesity | Phase 3 | Not yet recruiting | Universidade do Porto | 70 | 2027-01-01 | 2026-09-18 |
| A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems Orforglipron, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 192 | 2026-12-01 | 2026-10-13 |
| A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes eloralintide and tirzepatide, Eloralintide, Tirzepatide - Obesity | Phase 3 | Not yet recruiting | Eli Lilly and Company | 2115 | 2026-12-01 | 2026-11-03 |
| UBT251 Injection Phase Ⅲ Study (OSA-NPAP) UBT251, Placebo - Obstructive Sleep Apnea, Obesity | Phase 3 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 150 | 2026-12-01 | 2026-11-03 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk Eloralintide, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 3000 | 2026-12-01 | 2026-11-03 |
| Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes Olatorepatide, Placebo - Overweight or Obesity Without Diabetes | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 3000 | 2026-11-18 | 2026-10-26 |
| ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease Survodutide, Placebo matching survodutide - Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 600 | 2026-11-18 | 2026-11-12 |
| The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight Berobenatide, Placebo - Urinary Incontinence, Stress, Overweight and/or Obesity | Phase 3 | Not yet recruiting | Pfizer | 900 | 2026-11-17 | 2026-11-12 |
| A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity CagriSema, Semaglutide, Cagrilintide - Hypertension, Obesity | Phase 3 | Not yet recruiting | Novo Nordisk A/S | 1408 | 2026-11-11 | 2026-11-05 |
| SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Survodutide - Obesity | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 350 | 2026-11-07 | 2026-10-27 |
| A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents Ecnoglutide Injection, placebo with matching volume - Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities | Phase 3 | Not yet recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 192 | 2026-10-31 | 2026-09-23 |
| SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Survodutide, Placebo - Obesity | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 600 | 2026-10-31 | 2026-10-30 |
| Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk | Phase 3 | Not yet recruiting | Uppsala University | 250 | 2026-10-30 | 2026-09-08 |
| Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery Tegileridine (tegileridine fumarate injection, IV), Sufentanil - Pain Management, Overweight , Obesity | Phase 3 | Recruiting | The First Hospital of Jilin University | 148 | 2026-10-28 | 2026-11-03 |
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1500 | 2026-10-28 | 2026-11-05 |
| A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity Berobenatide, Placebo - Obesity, Overweight | Phase 3 | Recruiting | Pfizer | 432 | 2026-10-28 | 2026-11-06 |
| Vibegron for ENergy Thinking and Resilience in Aging Vibegron, Placebo - Obesity | Phase 3 | Recruiting | Wake Forest University Health Sciences | 40 | 2026-10-27 | 2026-10-28 |
Showing 20 of 678. Sign in to see all of them.
Obesity (599) · Diabetes Mellitus, Type 2 (88) · Weight Loss (55) · Diabetes Mellitus (34) · Motor Activity (33) · Hypertension (31) · Insulin Resistance (30) · Obesity, Morbid (30) · Prader-Willi Syndrome (25) · Cardiovascular Diseases (24) · Metabolic Syndrome (23) · Nutrition Disorders (22) · Sleep Apnea, Obstructive (21) · Body Weight (20)
Nutritional and Metabolic Diseases (676) · Overnutrition (674) · Pathological Conditions, Signs and Symptoms (657) · Nutrition Disorders (656) · Signs and Symptoms (656) · Body Weight (634) · Metabolic Diseases (173) · Glucose Metabolism Disorders (159) · Endocrine System Diseases (138) · Diabetes Mellitus (94) · Nervous System Diseases (68) · Obesity (60) · Body Weight Changes (58) · Hyperinsulinism (52)
semaglutide (64) · Tirzepatide (35) · Liraglutide (23) · Exercise (22) · Metformin (19) · Rimonabant (19) · orforglipron (15) · Diet (12) · Topiramate (12) · cagrilintide (12) · sibutramine (11) · Exenatide (10) · retatrutide (9) · bupropion hydrochloride, naltrexone hydrochoride drug combination (8) · BI 456906 (7)
Novo Nordisk A/S (62) · Eli Lilly and Company (52) · Pfizer (18) · Sanofi (18) · Yale University (13) · Amgen (12) · Boehringer Ingelheim (10) · Hoffmann-La Roche (8) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (8) · Mayo Clinic (8) · Merck Sharp & Dohme LLC (7) · Rhythm Pharmaceuticals, Inc. (7) · Abbott (6) · Assistance Publique - Hôpitaux de Paris (6) · AstraZeneca (6)
United States (339) · China (108) · Canada (104) · Germany (94) · Spain (87) · United Kingdom (85) · France (72) · Japan (66) · Australia (64) · Poland (62) · Argentina (60) · Mexico (59) · Brazil (56) · Italy (56) · Puerto Rico (56)
David Meeker, MD (7) · Craig Peterson (4)
PMID 27482610, PMID 27817208, PMID 28386912, PMID 28950422, PMID 30122305, PMID 38698650, PMID 39226070, PMID 23661689, PMID 26418188, PMID 27206567, PMID 27659698, PMID 27888609, PMID 28455281, PMID 28473337, PMID 35724304, PMID 36801984, PMID 40717199, PMID 41187013, PMID 41537305, PMID 41885866, PMID 42821228, PMID 26744025, PMID 26833744, PMID 27116910, PMID 27193270, PMID 27804269, PMID 28462892, PMID 33137293, PMID 33567185, PMID 33667417, PMID 36200477, PMID 36996264, PMID 37605636, PMID 37919617, PMID 38671361, PMID 39222642, PMID 39316288, PMID 39800653, PMID 40512543, PMID 40980163, PMID 41640675, PMID 42014131, PMID 42348366, PMID 42577069, PMID 11527911, PMID 12434728, PMID 12439645, PMID 14688154, PMID 15486569, PMID 15536230
2025 (29), 2023 (9), 2017 (7), 2008 (3), R01DK049587 (3), R01DK114075 (3), R01DK126637 (3), 2005 (2), 2014 (2), 2018 (2), R01AG025501 (2), R18DK083248 (2), U01DK074556 (2), 1RC1DK086132 (1), 2015 (1)